About: Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $101.41 (+1.87%)
ORKA NASDAQ Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc. share price
Atividade de preço de ORKA
Último preço
$ 101,410
Variação (24h)
1,86 USD (1,87%)
Volume
789.41K
Volume (média 4 sem.)
-
Abertura
$ 102,37
Variação do dia
$ 96,34 - $ 102,59
Fechamento anterior
$ 99,55
Último negócio
04 Nov, 9:00 pm GMT+0
Atrasado
04 Nov, 9:00 pm GMT+0
ORKA price performance
Atrasado
04 Nov, 9:00 pm GMT+0
ORKA details
quote.marketSignals